Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
d-cycloserine Considering our previous results with cfDNA in
2023-04-11

Considering our previous results with cfDNA in EGFR TKI-resistant NSCLC patients and growing evidence about different mutations in the ALK kinase domain as responsible for acquired resistance to ALK TKIs, we planned this study. Even if a next-generation sequencing approach after PD during crizotini
-
br Conflict of interest statement br Acknowledgements We
2023-04-11

Conflict of interest statement Acknowledgements We are very grateful to Maura Agate for her excellent editorial assistance. The work reported in this article was supported largely by the Italian MIUR. Introduction Atenolol is a selective β1-adrenergic receptor blocker that is orally effect
-
It is reported that Adiponectin is able to suppress
2023-04-11

It is reported that Adiponectin is able to suppress NF-κB pathway, and Bcr-Abl fusion oncoprotein in CML activates NF-κB by stimulating its nuclear translocation and also by enhancing its transactivation function [25], [26]. Therefore, it is tempting to hypothesize that NF-κB pathway might be involv
-
An AXL decoy receptor with enhanced GAS binding properties
2023-04-11

An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer Matrine and a murine breast cancer cell line in grafting assays in mice.
-
br Discussion In our current study we demonstrated that both
2023-04-11

Discussion In our current study, we demonstrated that both the metastatic and recurrent ovarian cancer tissues expressed lower levels of p62 when compared with the patient-matched primary tumor samples. High MK-4827 levels of p62 were associated with long progression-free survival of patients wit
-
Pyridostatin The Type A series contains of the
2023-04-11

The Type-A series contains 6 of the 11 confirmed hits, making it a highly attractive lead template. Seven (7) out of 8 Type-A series of 3-substituted-2-furoic acids are highly active (84–100% inhibition) at the high concentration of 100μM. We could deduce some interesting, albeit preliminary structu
-
Nimodipine receptor br The pathogenesis of AD
2023-04-11

The pathogenesis of AD and the targets of apelin Alzheimer's drugs Conclusions Introduction APJ, first identified from a human genomic library in 1993, belongs to a member of seven trans-membrane G protein-coupled receptor family. Its amino Nimodipine receptor sequence has 31% homology w
-
br Acknowledgements This work was supported in part
2023-04-11

Acknowledgements This work was supported, in part, by NIH grant R01-GM071760. Introduction The MADS box genes encode a eukaryotic family of transcriptional regulators involved in diverse and important biological functions. This class of proteins has been identified in yeasts, plants, insects,
-
Thalidomide is now a well
2023-04-11

Thalidomide is now a well known antiangiogenic agent. This property of thalidomide is being extensively researched upon, for its significant utility in the treatment of various malignant tumors. Studies show that thalidomide efficaciously inhibits various pro-angiogenic factors such as tumor necrosi
-
sh4 br AR signaling and urothelial cancer progression As sho
2023-04-11

AR signaling and urothelial cancer progression As shown in other types of malignancies, such as prostate cancer cells, it has been documented that androgens induce AR expression and its nuclear translocation as well as ARE promoter activity in urothelial cancer cells (Chen et al., 2003, Izumi et
-
Due to its unique histological architecture and blood
2023-04-11

Due to its unique histological architecture and blood supply, the lung is one of the most susceptible organs under uncontrolled systemic inflammatory circumstance [16]. Several studies have reported the anti-inflammatory benefits of metformin in acute lung injury induced by lipopolysaccharide (LPS),
-
The present study determined the effect
2023-04-10

The present study determined the effect of DCA on VSMC calcification in vitro and in atherosclerotic ApoE-/- mice in vivo. We found that N1-Methylpseudouridine non-toxic concentrations of DCA, did not affect VSMC viability, induced calcification of VSMC in culture and increased atherosclerotic vascu
-
Blocking the action of CREB with the C inhibitor together
2023-04-10

Blocking the action of CREB with the C646 inhibitor together with increasing Akt activation with the SC79 agonist is particularly interesting as it significantly reduced wound closure time from 7 days (which is required for complete closure of control hTECs exposed to DMSO) to only 4 days (when hTEC
-
The role of circulating physiologic concentrations of FGF in
2023-04-10

The role of circulating physiologic concentrations of FGF21 in glucose metabolism, however, remains unclear. Circulating FGF21 levels in obese and diabetic rodents, and in patients with type 2 diabetes are significantly higher than those in controls without diabetes [4], [5], [6]. On the other hand,
-
atp citrate lyase inhibitor The activation of the A BR subty
2023-04-10

The activation of the A2BR subtype triggers different intracellular metabolic pathways, often linked to the activation of adenylyl cyclase and increased levels of intracellular cAMP (Lynge et al., 2003, Bernareggi et al., 2015). The nAChR-channel atp citrate lyase inhibitor mediated by the cAMP/PKA
16627 records 345/1109 page Previous Next First page 上5页 341342343344345 下5页 Last page